ArticleJournal of the American Society of Nephrology : JASN2025

Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment.

Jennifer H Cox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.